Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained

Stephen T Vernon1,2, Sean Coffey1,3, Ravinay Bhindi1,2

  • 11 Cardiothoracic and Vascular Health, Kolling Institute and Department of Cardiology, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, Australia.

Insights

The number of ST-elevation myocardial infarction (STEMI) patients without standard modifiable cardiovascular risk factors (SMuRFs) is increasing. This highlights a growing need for new diagnostic and therapeutic strategies for heart attack patients.

Area of Science:

  • Cardiology
  • Public Health
  • Epidemiology

Background:

  • Standard Modifiable Cardiovascular Risk Factors (SMuRFs) management has improved cardiovascular disease (CVD) outcomes.
  • CVD remains the leading global cause of death.
  • Evolving risk factor profiles in ST-elevation myocardial infarction (STEMI) patients are suspected due to primary care advancements.

Purpose of the Study:

  • To investigate the trend of STEMI patients presenting without SMuRFs.
  • To test the hypothesis that the proportion of 'SMuRFless' STEMI cases has increased.

Main Methods:

  • Retrospective analysis of consecutive STEMI patients from a single center (2006-2014).
  • Assessment of the prevalence of SMuRFs (hypercholesterolaemia, hypertension, diabetes, smoking) at presentation.
  • Statistical analysis to determine trends and associations.

Main Results:

  • 25% of STEMI patients (132/695) had zero SMuRFs.
  • The proportion of SMuRFless STEMI patients significantly increased from 11% in 2006 to 27% in 2014 (OR 1.12 per year).
  • Decreases observed in hypercholesterolaemia and current smoking rates; no significant change in diabetes or hypertension prevalence.

Conclusions:

  • A substantial and increasing proportion of STEMI cases are not explained by traditional SMuRFs.
  • Urgent need for novel mechanisms, biomarkers, and targeted therapies for this growing patient group.
  • Further research is required to understand the outcomes and develop new treatments for SMuRFless STEMI.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
512
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
810
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
535
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.2K